Evolus stock
EOLSNASDAQEvolus, Inc., HealthcareISIN US30052C1071
44Score 44 out of 100, Weak
Price and trend
74 / 100
Price history
−1.6% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 53).
The price is 23% below its 52-week high. Largest decline in 9 years: 92% (June 2018 to October 2020).
Chart figures for advanced users
- SMA 50$7.66
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$6.36
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)53
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.94
- The lowest closing price of the last twelve months.
- Resistance$9.30
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Evolus, Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $475.23M, is number 71 of 77 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $297.18M (up 11.6% year on year) and a loss of $51.64M.
- For fiscal 2026, analysts expect on average revenue of $334.12M (up 12.4%) and adjusted earnings per share of −$0.03.
Show more
- MEQIRI Score 44 out of 100 (Weak): rank 467 of 702 in Healthcare, median 53.
- Our model puts fair value at $9.98, with the price 28% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 39.4% a year since 2020, Drug Manufacturers (Specialty & Generic) median 8.7%.Growth 70
Weaknesses
- DilutionShare count up 91% since 2020.Capital allocation 18
- Loss-makingLoss of $31.11M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$7.32M over the last 12 months.Fundamentals 17
Its standout strengths are valuation and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 45 to 44.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $6.65 and expensive above $19.96 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $8.11, at 7.8% it would be $12.80.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 13.9% on the twelve months before. Revenue turned from negative at the start of the period to positive ($297.18M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 65%, operating −13%, net −17%. Last 12 months: net −10%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 2 Mar 2027in 109 days
- Last reported
- 4 Nov 2026EPS reported −$0.09 (expected −$0.06)below expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 34.9% since 15 Oct 2026.
- Earnings per share
- −$0.03+31.6%
- Revenue
- $334.12M0.0%
- Earnings per share
- $0.34+34.9%
- Revenue
- $391.62M−0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +21.1%Low end of the 2026 revenue guidance raised to $330 million (upper end $337 million), adjusted gross margin guidance also raised.
“We are raising the lower end of our revenue guidance to $330 million while maintaining the upper end of $337 million effectively raising the midpoint of our guidance range to $333.5 million We are also raising our full year adjusted gross profit margin guidance.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $950,019 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Moatazedi DavidSale
2 Sept 2026, See Remarks
- Shares
- 105,108
- Price
- $9.04
- Value
- $950,019
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Evolus
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 44
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Ironwood PharmaceuticalsIRWD $802.92M72
- Collegium PharmaceuticalCOLL $775.33M51
- EvotecEVT.DE $613.98M32
- Alpha TeknovaTKNO $522.1M44
- KamadaKMDA $468.95M66
- Aquestive TherapeuticsAQST $448.71M29
- PharmaSGP HoldingPSG.DE $369.95M80
- BoironBOI.PA $366.51M56
ETFs that hold Evolus
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.03% | 0.35% | €1.25B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2019)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.